Currently, there are minimal and inadequate treatment options for fibrotic disease.

Would you please give us a brief introduction on the possible strategies to target HSCs using anti-fibrotic agents?

As lymphedema progresses, the outcomes from any treatment are less optimal because of adipose and fibrotic changes within the tissue.